Dormicum (Midazolam)

Dormicum (midazolam) is used in clinical practice for several short‑term therapeutic purposes.

• Pre‑operative sedation to calm patients before surgery.
• Anxiety reduction prior to diagnostic or therapeutic procedures.
• Short‑term management of acute insomnia.
• Adjunctive treatment of status epilepticus.
• Procedural sedation for minor interventions such as endoscopy.

Midazolam may cause a range of central nervous system effects, varying in frequency and severity.

Common

• Drowsiness or somnolence.
• Dizziness and light‑headedness.
• Impaired coordination or gait instability.
• Short‑term memory impairment.
• Headache.
• Nausea.

Serious

• Respiratory depression, especially with high doses or concurrent depressants.
• Severe hypotension.
• Paradoxical agitation or aggression.
• Anaphylactic reactions.
• Profound sedation leading to loss of consciousness.
• Withdrawal seizures with abrupt discontinuation after prolonged use.

When prescribing Dormicum, clinicians should consider several precautionary measures to ensure safe use.

• Assess respiratory function before administration, particularly in patients with pulmonary disease.
• Use the lowest effective dose for the shortest duration needed.
• Avoid use in patients with severe hepatic impairment.
• Contraindicated in individuals with known hypersensitivity to benzodiazepines.
• Exercise caution in pregnancy (Category D) and breastfeeding.
• Monitor for signs of dependence or tolerance with prolonged therapy.
• Adjust dose in elderly or debilitated patients due to increased sensitivity.

Midazolam interacts with various medications; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concomitant use with other central nervous system depressants (e.g., opioids, barbiturates, alcohol).
• Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir, which can increase midazolam levels.
• Potent CYP3A4 inducers (e.g., carbamazepine, phenytoin) that may reduce therapeutic effect.

Use with caution

• Certain antidepressants, particularly SSRIs, which may alter sedation levels.
• Anticonvulsants like valproate that can affect CNS depression.
• Antihistamines and some antihypertensives that may enhance sedative effects.
• Herbal supplements such as St. John’s wort, a CYP3A4 inducer.
• Other benzodiazepines or sedative‑hypnotics, requiring careful dose titration.